. Author manuscript; available in PMC: 2016 Mar 1.

Published in final edited form as: Cancer Causes Control. 2015 Jan 25;26(3):467–473. doi: 10.1007/s10552-015-0526-3

Table 2.

Lipid-polyp associations for pre-colonoscopy cholesterol extremes, Group Health, 1998–2007

Cholesterol measurement	Unit change for OR	Advanced adenoma cases (N=139) vs. controls (N=754)		Non-advanced adenoma cases(N=518) vs. controls (N=754)		Non-adenomatous polyp cases (N=380) vs. controls (N=754)
Cholesterol measurement	Unit change for OR	OR^a (95% CI)	P	OR^a (95% CI)	P	OR^a (95% CI)	P
Zenith LDL	+20 mg/dL	1.16 (1.03, 1.30)	0.01	1.07 (0.99, 1.15)	0.08	1.10 (1.01, 1.20)	0.03
Nadir HDL	−10 mg/dL	0.93 (0.79, 1.09)	0.37	0.94 (0.86, 1.05)	0.28	0.98 (0.88, 1.10)	0.72
Zenith TG	+40 mg/dL	1.09 (1.03, 1.16)	0.006	1.03 (0.98, 1.08)	0.21	1.02 (0.96, 1.07)	0.53
Zenith TC	+20 mg/dL	1.09 (1.02, 1.18)	0.02	1.03 (0.98, 1.09)	0.29	1.05 (0.99, 1.11)	0.12

OR is adjusted for age at colonoscopy, sex, race, data-collection period, education, BMI, NSAID use, family history of CRC, estrogen-only use (in women), estrogen-plus-progestin use (in women), cigarette smoking, alcohol consumption, diabetes mellitus, fruit servings per day, vegetable servings per day, recreational and exercise physical activity, prior endoscopy (approximately 2 years before study colonoscopy), and data-collection period.

Abbreviations: BMI, body mass index; CI, confidence interval; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; NSAID, nonsteroidal anti-inflammatory drug; OR, odds ratio; TC, total cholesterol; TG, triglycerides.